Uncategorized

SOUTH SAN FRANCISCO, Calif. – October 13, 2022 – Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation on the company’s unique engineering platform, called the Gene Expression Modulation System (GEMS), at the co-hosted Solebury / BMO Fall Private Company Showcase. “We are excited … Read more

SOUTH SAN FRANCISCO, Calif. — October 6, 2022 — EPIC BIO, a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCas protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York. The event is co-hosted by … Read more

– $55 million Series A financing will advance the company’s robust preclinical pipeline and ongoing discovery efforts –  – Epic holds exclusive license to smallest known Cas protein, enabling in vivo delivery via AAV vector to wide range of target organs – –  Lead program in facioscapulohumeral muscular dystrophy (FSHD) on track for clinical initiation … Read more